Discussion: The role, position, and function of the FDA-The past, present, and future.
作者信息
Fleming Thomas R, Demets David L, McShane Lisa M
机构信息
University of Washington, Seattle, WA, USA.
University of Wisconsin, Madison, WI, USA.
出版信息
Biostatistics. 2017 Jul 1;18(3):417-421. doi: 10.1093/biostatistics/kxx023.
Abstract
摘要
相似文献
1
Discussion: The role, position, and function of the FDA-The past, present, and future.
Biostatistics. 2017 Jul 1;18(3):417-421. doi: 10.1093/biostatistics/kxx023.
2
Discussion: The FDA is Unprepared for Personalized Medicine.
Biostatistics. 2017 Jul 1;18(3):403-404. doi: 10.1093/biostatistics/kxx018.
3
FDA dependence on drug industry.
J Natl Med Assoc. 2005 Jul;97(7):1039-40.
4
Model-Informed Drug Development: A Regulatory Perspective on Progress.
Clin Pharmacol Ther. 2019 Jul;106(1):91-93. doi: 10.1002/cpt.1475. Epub 2019 Jun 4.
5
Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
MedGenMed. 2006 Oct 30;8(4):22.
6
Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.
Genet Med. 2019 Mar;21(3):542-544. doi: 10.1038/s41436-018-0099-0. Epub 2018 Jul 10.
7
The voices of patients and families must be heard.
Epilepsy Behav. 2019 May;94:307. doi: 10.1016/j.yebeh.2019.01.013. Epub 2019 Mar 22.
8
Olestra and the FDA.
N Engl J Med. 1996 Apr 11;334(15):984-6. doi: 10.1056/NEJM199604113341511.
9
Financial conflicts of interest and the Food and Drug Administration's Advisory Committees.
N Engl J Med. 2005 Jul 14;353(2):116-8. doi: 10.1056/NEJMp058108.
10
Conflicts of Interest Among Patient and Consumer Representatives to U.S. Food and Drug Administration Drug Advisory Committees.
Ann Intern Med. 2016 Oct 18;165(8):606-607. doi: 10.7326/L16-0031.
引用本文的文献
1
Reforming Food, Drug, and Nutraceutical Regulations to Improve Public Health and Reduce Healthcare Costs.
Foods. 2025 Jun 30;14(13):2328. doi: 10.3390/foods14132328.
2
Primum non nocere: Toward a Greater Understanding of the Potential for Harm in Psychological Treatments for Youth.
Res Child Adolesc Psychopathol. 2025 May;53(5):597-607. doi: 10.1007/s10802-025-01323-z. Epub 2025 Apr 30.
3
Nanomedicine Therapies for Pediatric Diseases.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Sep-Oct;16(5):e1996. doi: 10.1002/wnan.1996.
4
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023.
Biomedicines. 2024 Sep 2;12(9):1992. doi: 10.3390/biomedicines12091992.
本文引用的文献
1
Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance.
JAMA. 2017 Feb 21;317(7):693-694. doi: 10.1001/jama.2017.0410.
2
Clinical trials: discerning hype from substance.
Ann Intern Med. 2010 Sep 21;153(6):400-6. doi: 10.7326/0003-4819-153-6-201009210-00008.
3
Sensible approaches for reducing clinical trial costs.
Clin Trials. 2008;5(1):75-84. doi: 10.1177/1740774507087551.
Zotero 插件